Table 1.
Macroscopic evaluation of gastric mucosa
| Groups | n | Weight (gr) | GML count | GML area mm2 |
| Sham | 8 | 223.50 ± 18.40 (200-249) | 0 | 0 |
| Indomethacin | 8 | 225.00 ± 13.77 (201-248) | 6.25 ± 3.49 (1-11)a | 21.00 ± 12.35 (1-36)b |
| Famotidine 5 (F5) | 8 | 223.25 ± 13.13 (203-236) | 4.12 ± 2.47 (2-8) | 8.62 ± 2.97 (3-12) |
| Famotidine 20 (F20) | 8 | 224.75 ± 14.78 (200-247) | 2.37 ± 4.43 (0-13) | 0.94 ± 2,06 (0-6)d |
| Vardenafil 2 (V2) | 8 | 221.12 ± 13.27 (204-242) | 4.37 ± 3.06 (0-8) | 6.62 ± 5.87 (0-16)e |
| Vardenafil 10 (V10) | 8 | 224.12 ± 15.16 (202-250) | 1.25 ± 1.38 (0-3)cg | 0.75 ± 0.88 (0-2)dg |
GML: Gastric mucosal lesion. The values are presented as mean ± SD, (min-max).
a
P < 0.05,
b
P < 0.001 vs all other groups;
c
P < 0.05,
d
P < 0.001 vs group F5;
e
P < 0.05 vs group F20;
g
P < 0.05 vs group V2.